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February 3, 2009:457–9Therefore, with the limitations of the National Hospital Dis-
harge Survey, we are unable to conclude that the increase in the
revalence of diastolic heart failure contributed to the finding of
ncreasing heart failure hospitalization over the past 25 years.
Jing Fang, MD
ora L. Keenan, PhD
eorge A. Mensah, MD
anet B. Croft, PhD
Centers for Disease Control and Prevention
770 Bulford Hwy, NE, MS K-47
tlanta, Georgia 30341-3717
-mail: jfang@cdc.gov
doi:10.1016/j.jacc.2008.10.030
EFERENCES
. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related
hospitalization in the U.S., 1979–2004. J Am Coll Cardiol 2008;52:
428–34.
. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield
MM. Trends in prevalence and outcome of heart failure with preserved
ejection fraction. N Engl J Med 2006;355:251–9.
levated N-Terminal Pro-B-Type
atriuretic Peptide Levels:
he Effect of Chronic
bstructive Pulmonary Disease
e read with great interest the recent article by Daniels et al. (1)
n which the investigators reported that detectable cardiac troponin
and N-terminal pro-B-type natriuretic peptide (NT-proBNP)
ere both associated with increased all-cause and cardiovascular
eath in healthy older adults.
NT-proBNP was previously identified as a prognostic cardiac
isk marker associated with increased mortality. NT-proBNP is
eleased by cardiac myocytes in response to wall stress in conditions
ssociated with volume overload as in heart failure and chronic
idney disease, pressure overload as in patients with heart valve
bnormalities, and ischemia owing to coronary disease. In the
resent study, the association remained even after participants with
aseline coronary heart disease were excluded, which was 30% of
he subjects with elevated (450 pg/ml) NT-proBNP levels.
However, the authors might have overlooked the effect of
hronic obstructive pulmonary disease (COPD) on NT-proBNP
evels. COPD is associated with cardiovascular disease and is an
ndependent risk factor for cardiovascular morbidity and mortality
2). We recently investigated the relationship between COPD,
oth the presence and severity, and NT-proBNP levels in 376
atients. To mitigate the influence of heart failure, chronic kidney
isease, and myocardial ischemia, we adjusted for history of angina
ectoris, myocardial infarction, heart failure, and renal function. In
ddition, all patients had resting left ventricular function of more
han 40% using echocardiography. The severity of COPD was assessed using pulmonary function tests with the GOLD (Global
nitiative for Chronic Obstructive Lung Disease) classification.
e found COPD to be an independent risk factor for increased
T-proBNP levels, and the levels increased with the severity of
OPD.
The underlying mechanism is likely to be pulmonary hyperten-
ion and right ventricular dysfunction caused by pulmonary arterial
ressure overload (3). COPD may induce wall stretching, ven-
ricular dilation, and/or increased vascular pressures, which may
romote the secretion of the neurohormone NT-proBNP.
ecause COPD is common in the elderly population (affecting
early 35% of this population) (4), the addition of spirometric data
o the analysis by Daniels et al. (1) would have been very
nteresting and informative. The less severe forms of COPD are
ften asymptomatic and therefore frequently underestimated, es-
ecially in the elderly. Thus, the presence of underlying COPD
ight have contributed to the observed correlation between
T-proBNP and outcome in this elderly population.
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eply
e thank Dr. van Gestel and colleagues for their interest in our
ork (1). They wonder whether the presence of underlying chronic
bstructive pulmonary disease (COPD) might have contributed to
he strong association between N-terminal pro-B-type natriuretic
eptide (NT-proBNP) and outcomes in the Rancho Bernardo
tudy. We did not find this to be the case.
Dr. Van Gestel and colleagues stated that COPD affects nearly
5% of the elderly population; however, the article that they
eference actually found this incidence only in current smokers (2).
he cumulative incidence of COPD was only 14% in ex-smokers
nd 12% in never-smokers.
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February 3, 2009:457–9The Rancho Bernardo Study had a low prevalence of smoking,
ith only 4% reporting a current smoking habit. Consistent with
his, the prevalence of COPD in our cohort, as determined by
elf-report and review of history and medications, was extremely
ow at only 6%. Median NT-proBNP levels did not differ based on
he presence or absence of COPD (208 pg/ml vs. 171 pg/ml, p 
.20), and adjusting for a history of COPD did not significantly
nfluence the association of NT-proBNP with all-cause death and
ardiovascular death: hazard ratios per 1-U log increase in NT-
roBNP levels were 1.70 (95% confidence interval [CI]: 1.24 to
.33, p  0.001) versus 1.67 (95% CI: 1.21 to 2.29) for all-cause
eath and 1.97 (95% CI: 1.19 to 3.26, p 0.009) versus 1.93 (95%
I: 1.17 to 3.19) for cardiovascular death in Cox proportional
azards models adjusted for age, sex, and other cardiovascular risk
actors with and without COPD in the model.
Spirometry was not performed at the same Rancho Bernardo
tudy visit when NT-proBNP was measured, which could have led
o an underestimation of the true prevalence of COPD. However,
levated natriuretic peptide levels in the setting of COPD are likely
ue to right ventricular dysfunction secondary to pulmonary
ypertension; thus, individuals with asymptomatic COPD are
nlikely to have significantly elevated levels of natriuretic peptide
nd would therefore be unlikely to explain a significant proportion
f the association of NT-proBNP with all-cause and cardiovascu-
ar mortality (3).Lori B. Daniels, MD, MAS, FACC
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